Literature DB >> 868834

Hepatic sensitivity to imipramine.

G A Weaver, D Pavlinac, J S Davis.   

Abstract

A case of significant hepatic reaction related to imipramine is presented, documented by challenge with imipramine and liver biopsy. The mechanism, while not entirely clear, is presumed to involve hypersensitivity or induction of toxic metabolites.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 868834     DOI： 10.1007/bf01072511

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN： 0002-9211


  11 in total

1.  JAUNDICE DURING IMIPRAMINE TREATMENT.

Authors:  P C HOAKEN
Journal:  Can Med Assoc J       Date:  1964-06-13       Impact factor: 8.262

Review 2.  CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS.

Authors:  G L KLERMAN; J O COLE
Journal:  Pharmacol Rev       Date:  1965-06       Impact factor: 25.468

3.  The treatment of depressive conditions with imipramine (G 22355).

Authors:  H E LEHMANN; C H CAHN; R L DE VERTEUIL
Journal:  Can Psychiatr Assoc J       Date:  1958-10

4.  Preliminary evaluation of tofranil in a combined in-patient and out-patient setting.

Authors:  S MALITZ; B WILKENS; H ESECOVER
Journal:  Can Psychiatr Assoc J       Date:  1959

5.  Indications for electro-shock, tofranil and psycho therapy in the treatment of depressions.

Authors:  H HOFF
Journal:  Can Psychiatr Assoc J       Date:  1959

6.  [Treatment of depressive states with an iminodibenzyl derivative (G 22355)].

Authors:  R KUHN
Journal:  Schweiz Med Wochenschr       Date:  1957-08-31

7.  Progress in hepatology. Metabolic activation of drugs to toxic substances.

Authors:  J R Mitchell; D J Jollows
Journal:  Gastroenterology       Date:  1975-02       Impact factor: 22.682

8.  Lethal hepatic necrosis after therapy with imipramine and desipramine.

Authors:  W J Powell; J Koch-Weser; R A Williams
Journal:  JAMA       Date:  1968-10-14       Impact factor: 56.272

9.  Antidepressants and barbiturates.

Authors:  G D Burrows; B Davies
Journal:  Br Med J       Date:  1971-10-09

10.  Cholestatic jaundice during imipramine therapy.

Authors:  M H Short; J M Burns; M E Harris
Journal:  JAMA       Date:  1968-11-18       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.